Study findings from Anaconda Biomed about the ANAIS study published in the American Journal of Neuroradiology
In a significant development for endovascular stroke treatment, the ANAIS Study has evaluated the safety and performance of Anaconda Biomed's ANA funnel catheter. The study, conducted prospectively across three centers in Spain, focused on the treatment of large vessel occlusion acute ischemic stroke.
The ANA5, a funnel catheter designed for neurovascular procedures, has shown promising results. During thrombectomy procedures, especially in combination with stent retrievers, the ANA5 may enhance clot removal. Its large lumen, matching the diameter of the target artery, and radiopaque, self-expanding funnel covered with a continuous sealing coating, facilitate the delivery of intravascular devices.
The primary efficacy endpoint-successful reperfusion (eTICI 2b50-3) within three passes-was achieved in 70% of patients in the intention-to-treat (ITT) population and 81% in the per-protocol (PP) population. When the ANA device was deployed in the ICA C2-C3 segment and continuous aspiration was applied, first pass effect, or FPE, (eTICI 2c-3) was achieved in 83% of the cases. Notably, no severe device-related adverse events or symptomatic intracranial hemorrhages were observed at 24 hours.
Hendrik Lambert, Chief Medical Officer at Anaconda Biomed, expressed gratitude to the investigators, centers, and patients who contributed to the ANAIS Study. The high rates of FPE observed in the ANAIS Study are being implemented in the ongoing ATHENA clinical trial.
However, as of now, no latest developments or specific findings about the ATHENA trial using Anaconda Biomed's ANA funnel catheter in stroke treatment have been found or reported. The search results do not mention the ATHENA trial related to stroke or the ANA funnel catheter. To stay updated on this particular stroke trial, it may be necessary to check specialized stroke or neurovascular intervention trial registries, Anaconda Biomed’s official releases, or clinical trial databases like ClinicalTrials.gov.
In other news, Anaconda Biomed has enrolled the first U.S. patient in the ATHENA study, and the company has appointed a new CEO. Additionally, Anaconda Biomed, S.L. has published results from the ANAIS Study in the American Journal of Neuroradiology, and the company has received CE Mark for the ANA5 Funnel Catheter. Deployment of the ANA5 enables temporary local flow restriction, and the device's large lumen matches the diameter of the target artery, further enhancing its utility in neurovascular procedures.
The ANA funnel catheter, used particularly in neurovascular procedures and thrombectomy, has demonstrated potential in the treatment of medical-conditions like stroke, due to its large lumen and self-expanding design. In the future, technology advances like the ATHENA clinical trial may further improve stroke health-and-wellness outcomes, especially in treating neurological-disorders such as large vessel occlusion acute ischemic stroke. However, specific findings about the ATHENA trial using the ANA funnel catheter are yet to be reported.
